• Developed an ELSIPOT assay with primary mouse splenocytes to measure the antigen specific T cell response and hit rate of our polyepitope mRNA-LNP vaccine candidates to demonstrate potency and the broad response across diverse MHC-I.• Developed a whole blood RT-qPCR assay to measure the antigen specific T cell response of our mRNA-LNP vaccine in clinical samples and transferred it to our CRO for use in a phase I clinical trial for personalized cancer vaccines.• Analyzed the polyfunctionality of the CD8 and CD4 T cell responses triggered post-vaccination by intracellular staining (ICS) flow cytometry and cytokine release ELISAs.• Screened novel LNP formulations for T cell activation and transfection efficiency by flow cytometry and ELISPOT.• Tested mRNA vaccine candidates for immunostimulatory activity in human immune cells by cytokine release ELISA to support the optimization of purification processes and demonstrate that our platform is designed to reduce the risk of injection site reactions.

• Developed a cell-based ELISA for use as a potency assay and as a neutralizing ADA assay for use in Phase 3 clinical studies.• Collaborated on the development of an ex vivo antigen presentation assay where T cell activation is measured via flow cytometry to rank drug candidates and further understand the mechanism of action or our autoimmune disease targeting therapies. • Investigated the Treg phenotype induced by drug treatment in various tissue by qRT-PCR for mechanism of action studies.• Supported Clin Ops by managing site supply and lab sample logistics for a phase 1 clinical trial in Multiple Sclerosis. GCP trained.• Managed supplies for 15 clinical sites and the depot inventory. • Trained clinical site staff on sample collection and shipment procedures during Site Initiation Visits, protocol amendment meetings, and any ad-hoc retraining that was required.• Tracked the status of all clinical samples, managed the running of samples at external vendors, and analyzed all incoming exploratory biomarker data. Ensured that data readouts adhered to study milestone timelines.• Drove the writing and approval of Data Transfer/Release Agreements for each external vendor, Lab Logistics Worksheet, and Lab Manual. Assisted in updating of the Study Protocol and ICF.

• Developed flow cytometry-based ligand internalization assays and cell cytotoxicity assays for IND enabling studies. Wrote technical reports summarizing the findings from both assays to enable the filing of 2 INDs in the same year. • Investigated the downstream signaling that occurs upon ligand binding and internalization for our mechanism of action in autoimmune disease. Screened for phosphoprotein changes in cells treated with drug via protein arrays, confirmed hits with WB and qRT-PCR, and looked for wider gene expression changes via RNAseq.• Developed an in vitro antigen processing and presenting assay via cocultures of engineered antigen presentation cells and antigen reactive T cells with ELISA and flow cytometry-based readouts. • Collaborated with the Translational Team to develop a qRT-PCR based assay for biomarker development. • Led molecular biology efforts to build a modular cloning plasmid for antibody expression and to optimize and standardize our expression protocols. Optimized protein expression for new potential indications with either HEK, yeast, or baculovirus.

• Speaheaded an affinity maturation campaign of clinical fAb candidates. Generated randomized CDR libraries and performed phage display, selections, screening of the outputs via ELISA, and all optimization needed for each step therein. Organized team discussions and characterization of affinity matured clones. We patented our findings, and I presented a poster outlining the campaign at PEGS Boston. • Developed 2 stable knock-in cell lines in CHO cells and a CRISPR-Cas9 mediated knockout cell line in HEPG2 cells to generate tool cell lines. • Cloned and expressed reagent proteins and antibodies and characterized various primary and immortalized cell lines via qRT-PCR, flow cytometry, and western blot to build out our tools for a target identification effort.

• Generated multiple cell lines, both knock-in and knock-out lines, with CRISPR-Cas9 for assay development, target validation, and high throughput screens. Presented the development of one of the knock-out lines in a poster presentation.• Investigated the role a key target in neurodegenerative disease played in ITIM/ITAM signaling in microglia and myeloid cells via phospho-western blot and ELISA with the knock-in and knock-out cell lines. • Developed a cytokine release MSD/ELISA assay to further support proof-of-concept studies. • Characterized a line of neurons derived from a novel hESC line via immunofluorescence, imaging, and qRT-PCR to assess how active and physiologically relevant the neurons were. Presented the development and characterization of this cell line in a poster presentation.

I assisted in formulation development and biophysical characterization of biologic drug candidates. Researched the effects of buffer salt concentration on protein-protein interactions and stability. I analyzed protein stability by UV and Fluorescence Spectrophotometry, Size Exclusion Chromatography, Capillary Isolelectric Focusing, and Dynamic Light Scattering.

I assisted in prepping patients for surgery by taking vital signs and hooking patients up to heart monitors. I was in charge of facilitating the flow of patients through the unit by preparing patient rooms, cleaning and restocking equipment, and assisting in patient transport.